Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

WUXI ADVANCED THERAPIES INC.

WUXI ADVANCED THERAPIES INC. is a federal contractor, registered under UEI DFL9LER9JCD9 and CAGE code 8PGV3. It has been awarded $103,000 in federal contracts. Primary work spans Medicinal and Botanical Manufacturing. Top awarding agencies include Department Of Health And Human Services.

Contact Information

Registration and classification details

Registration

UEI Code

DFL9LER9JCD9

CAGE Code

8PGV3

Entity Structure

Corporate Entity (Not Tax Exempt)

Established

N/A

Business Classifications

For Profit Organization

NAICS Codes

541714Research and Development in Biotechnology (except Nanobiotechnology)(Primary)
621511Medical Laboratories

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

Wuxi Advanced Therapies Inc. specializes in advanced therapeutic research and development, with core capabilities centered on biopharmaceutical innovation, process development, and translational science. The company leverages expertise in cell and gene therapy platforms, vector engineering, and GMP-...

Wuxi Advanced Therapies Inc. specializes in advanced therapeutic research and development, with core capabilities centered on biopharmaceutical innovation, process development, and translational science. The company leverages expertise in cell and gene therapy platforms, vector engineering, and GMP-compliant manufacturing processes to support preclinical and clinical-stage product advancement. Technical strengths include analytical method validation, quality by design (QbD) frameworks, and regulatory strategy alignment for FDA submissions under CBER guidelines. Their approach emphasizes scalable, patient-centric therapeutic solutions with a focus on precision medicine applications, differentiating through integrated process optimization and early-stage risk mitigation in complex biologic development. No agency relationships can be inferred from available award data, as no recent contracts or performance records are documented. Consequently, there is no demonstrable history of engagement with federal, state, or defense agencies to characterize specific programmatic support or procurement patterns. The primary NAICS code 541714 indicates focus on research and development in the biotechnological services sector, encompassing laboratory-based therapeutic discovery, biomolecular characterization, and preclinical testing services. This positions the company within the life sciences R&D vertical, serving pharmaceutical sponsors, academic medical centers, and emerging biotech firms requiring specialized development support without direct government contract history. Wuxi Advanced Therapies Inc. is structured as a 2L entity, indicating a small business with limited organizational scale. The company operates from Philadelphia, PA, with no publicly disclosed government certifications such as 8(a), HUBZone, or SDVOSB. Its market presence is defined by technical specialization rather than broad federal procurement engagement, reflecting a niche, research-driven profile in the biopharmaceutical innovation ecosystem.

Key Performance Metrics

Awards Count

1

All time

Active

0

Currently performing

Completed

1

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency
Awards by NAICS
Awards by Agency Over Time
Awards by Place of Performance

Compete with WUXI ADVANCED THERAPIES INC.

Track the contractors you bid against, and the work they win

Award history, agency mix, and NAICS coverage for WUXI ADVANCED THERAPIES INC.

AI-powered matching against your own capabilities and past performance

Teaming and subcontracting signals on every award

Automated alerts when a competitor wins in your market

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS

Open opportunities in WUXI ADVANCED THERAPIES INC.'s top NAICS codes and agencies

NAICS: 325411
New
DIBBS
CHLORHEXIDINE GLUCONAT
Solicitation # SPE2DP-27-T-0091
Solicitation SPE2DP-27-T-0091 is a request for quotations issued by the DLA Troop Support Medical Supply Chain Pharm FSA for the procurement of Chlorhexidine Gluconate cleansing solution (NSN 6505016755990). The requirement consists of two cases, with each case containing eight 16oz dispenser refill bottles of 1% / 61% surgical scrub. The items must be stored between 20-25 degrees Celsius and have a total shelf life of 24 months. Delivery is specified as FOB Destination to Camp Pendleton, California, with a required delivery date of October 14, 2026, and a delivery timeframe of five days after the order is placed. The contractor must adhere to strict packaging and marking standards, specifically Medical Marking Standard No. 1, which supersedes MIL-STD-129. Packaging must be commercial and sealed to protect contents from damage, with palletization following RP001 requirements. Because the material is flammable, the supplier must provide Safety Data Sheets (SDS) and hazard communication labels in accordance with 29 CFR 1910.1200 and Federal Standard No. 313-E prior to award. Invoicing and receiving reports must be processed electronically through the Wide Area WorkFlow (WAWF) system. The solicitation is assigned NAICS code 325411 and incorporates various FAR and DFARS clauses, including the Buy American Act and cybersecurity requirements for safeguarding covered defense information.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

3 days ago

DEADLINE

in 3 days
View Details
NAICS: 325411
New
DIBBS
REHYDRATION SALTS FOR
Solicitation # SPE2DP-27-T-0084
Solicitation SPE2DP-27-T-0084, issued by the DLA Troop Support Medical Supply Chain Pharm FSA, is for the procurement of five cases of fruit punch flavored electrolyte oral hydration powder. Each case contains 100 packets of 21 grams each, providing sodium, potassium, chloride, citrate, magnesium, zinc, 16 grams of carbohydrates, and 65 calories per packet. This FDA-regulated product requires reconstitution with water and has an extendable shelf life of 60 months. The requirement is identified by NSN 6505-01-731-1586 and is associated with Drip Drop Hydration Inc. Delivery is required within five days of order, with an original required delivery date of October 13, 2026. Shipping is FOB Destination to locations in Norman and Oklahoma City, Oklahoma, using the fastest traceable means. Packaging must be commercial and adhere to MIL-STD-2073-1E and DLA requirement RP001, while marking must comply with Medical Marking Standard No. 1. Inspection and acceptance will occur at the destination per FAR 52.246-2. The contract incorporates various FAR and DFARS clauses, including those regarding the Buy American Act, safeguarding covered defense information, and combating trafficking in persons. Invoicing must be processed electronically through the Wide Area WorkFlow system. Quotations are due by October 19, 2026, and must include all necessary representations and certifications, specifically regarding small business status and domestic material disclosure.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

4 days ago

DEADLINE

in 3 days
View Details